McGee, Sean L. http://orcid.org/0000-0001-6953-106X
Hargreaves, Mark
Article History
Accepted: 29 May 2020
First Online: 6 July 2020
Competing interests
: Both authors hold equity in Imitex Pty Ltd., a drug discovery start-up that was spun out from papers published by the authors that have identified the MEF2-class IIa HDAC axis as a druggable target to replicate aspects of the exercise adaptive response. This pathway is discussed in the current manuscript, along with many others that have been studied within the field.